Picture of Neoleukin Therapeutics logo

NLTX — Neoleukin Therapeutics Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Momentum

Relative Strength (%)
1m-26.79%
3m
6m
1yr
Volume Change (%)
10d/3m
Price vs... (%)
52w High-70.97%
50d MA
200d MA

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for NLTX

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of Neoleukin Therapeutics EPS forecast chart

Profile Summary

Neoleukin Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in providing immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. The Company uses computational methods to design proteins that demonstrate specific pharmaceutical properties. Its primary areas of focus are oncology, inflammation and autoimmunity. Its technology, Neoleukin platform, uses a set of advanced computational algorithms and methods to design functional de novo proteins. Neoleukin’s lead program, NL-201, is a computationally designed de novo protein therapeutic. NL-201 is designed for use as a single-agent or in combination with complementary therapeutic modalities. NL-201 has also shown promise in combination with allogenic cell therapy to expand and maintain populations of transplanted CAR-T and NK cells.

Directors

Last Annual
December 31st, 2020
Last Interim
September 30th, 2021
Incorporated
May 25th, 2007
Public Since
March 12th, 2014
No. of Employees
70
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Market
Shares in Issue
42,428,134

NLTX Share Price Performance

Latest News for NLTX

Upcoming Events for NLTX

Q4 2021 Neoleukin Therapeutics Inc Earnings Release

Q1 2022 Neoleukin Therapeutics Inc Earnings Release

Neoleukin Therapeutics Inc Annual Shareholders Meeting

Similar to NLTX

Picture of 4d Pharma logo

4d Pharma

us flag iconNASDAQ Global Market

Picture of 89bio logo

89bio

us flag iconNASDAQ Global Market

Picture of Acceleron Pharma logo

Acceleron Pharma

us flag iconNASDAQ Global Market

Picture of AcelRx Pharmaceuticals logo

AcelRx Pharmaceuticals

us flag iconNASDAQ Global Market

Picture of AC Immune SA logo

AC Immune SA

us flag iconNASDAQ Global Market

FAQ

Or unlock with your email

Or unlock with your email